Unnamed: 0,title,date,stock,sentiment
72999.0,Ampio Says Filed IND Applications For Ampion,2020-05-22 08:02:00-04:00,AMPE,neutral
73000.0,Ampio Reports Acceptance Of Publication On The Potential Benefits Of Nebulized Ampion For COVID-19 Coronavirus Patients,2020-05-11 08:24:00-04:00,AMPE,positive
73001.0,Ampio Pharma Reports Acceptance Of Publication On Potential Benefits Of Nebulized Ampion For Coronavirus Patients,2020-05-11 08:21:00-04:00,AMPE,positive
73002.0,Ampio Pharma Highlights FDA Application For Ampion To Treat Coronavirus-Induced Acute Respiratory Distress Syndrome Featured In FOX News Video,2020-04-02 09:11:00-04:00,AMPE,negative
73003.0,Ampio Suspends Patient Enrollment In Phase 3 Study Of Ampion For Severe Osteoarthritis Of The Knee And Explores Other Options To Complete Trial  As A Result Of Coronavirus Concerns,2020-03-24 07:03:00-04:00,AMPE,negative
73004.0,Ampio Says Is Preparing Expanded Access FDA Protocol To 'Study Nebulized Ampion as a Treatment for Moderate to Severe Acute Respiratory Distress Syndrome Associated with' Coronavirus,2020-03-24 06:33:00-04:00,AMPE,negative
73005.0,Ampio Pharma 10-K Just Out; Includes Message About Co.'s Independent Registered Public Accounting Firm Having Expressed Substantial Doubt As To Co.'s Ability To Continue As A Going Concern,2020-02-21 06:21:00-05:00,AMPE,positive
73006.0,"Roth Capital Initiates Coverage On Ampio Pharmaceuticals with Buy Rating, Announces $4 Price Target",2019-12-19 06:38:00-05:00,AMPE,neutral
73007.0,Ampio Pharmaceuticals shares are trading higher after Roth Capital Partners initiated coverage on the stock with a Buy rating.,2019-12-18 16:15:00-05:00,AMPE,positive
73008.0,"Roth Capital Partners Initiates Coverage On Ampio Pharmaceuticals With Buy Rating, Says Mid-2020 Release Of AP-013 Data Will Be A 'Positive, Material Investment Catalyst'",2019-12-18 16:11:00-05:00,AMPE,neutral
73009.0,"Ampio Pharma Offers Update On Continued Progress Of AP-013 Phase 3 Trial, Manufacturing Facility",2019-10-10 08:35:00-04:00,AMPE,positive
73010.0,"UPDATE: Ampio Says Co. Consented/Enrolled 661 Patients Of Which 423 Have Been Injected, Added 52 Patients Approved For Injection",2019-09-17 08:34:00-04:00,AMPE,positive
73011.0,"Ampio Pharma Reports FDA Gave Written Guidance That Prior AP-003-A Study Qualifies As Pivotal Trial, Successful Passing Of Current Study Would Support Filing Of Biologics License Application",2019-09-17 08:34:00-04:00,AMPE,positive
73012.0,ThinkEquity Initiates Coverage On Ampio Pharmaceuticals With Buy Rating And $5 Price Target,2019-08-19 09:41:00-04:00,AMPE,neutral
73013.0,Ampio Pharma Offers Update On Special Protocol Assessment Trial,2019-07-25 08:47:00-04:00,AMPE,positive
73014.0,60 Biggest Movers From Yesterday,2019-06-18 04:54:00-04:00,AMPE,neutral
73015.0,Mid-Afternoon Market Update: Crude Oil Down 1.5%; C&J Energy Services Shares Spike Higher,2019-06-17 14:52:00-04:00,AMPE,negative
73016.0,44 Stocks Moving In Monday's Mid-Day Session,2019-06-17 12:23:00-04:00,AMPE,neutral
73017.0,Mid-Day Market Update: Sotheby's Jumps On Acquisition News; Flex Pharma Shares Slide,2019-06-17 12:12:00-04:00,AMPE,positive
73018.0,Mid-Morning Market Update: Markets Open Higher; Pfizer To Acquire Array BioPharma For $48/Share,2019-06-17 10:17:00-04:00,AMPE,neutral
73019.0,"Ampio Pharmaceuticals, Inc. shares are trading lower after the company priced a 25.32 million share common stock offering at $0.40 per share.",2019-06-17 08:27:00-04:00,AMPE,positive
73020.0,Ampio Pharmaceuticals Prices 25.32M Share Common Stock Offering At $0.40/Share,2019-06-17 08:26:00-04:00,AMPE,positive
73021.0,28 Stocks Moving In Monday's Pre-Market Session,2019-06-17 08:06:00-04:00,AMPE,neutral
73022.0,A Peek Into The Markets: US Stock Futures Edge Higher Ahead Of Economic Data,2019-06-17 06:37:00-04:00,AMPE,neutral
73023.0,46 Biggest Movers From Friday,2019-06-17 06:25:00-04:00,AMPE,neutral
73024.0,"5 Stocks To Watch For June 17, 2019",2019-06-17 05:49:00-04:00,AMPE,neutral
73025.0,Ampio Pharmaceuticals shares are trading lower after the company reported a common stock offering with no disclosed size.,2019-06-14 16:03:00-04:00,AMPE,negative
73026.0,"Ampio Pharmaceuticals Reports Common Stock Offering, No Size Disclosed",2019-06-14 16:01:00-04:00,AMPE,negative
73027.0,35 Stocks Moving In Friday's Mid-Day Session,2019-06-14 12:11:00-04:00,AMPE,neutral
73028.0,Ampio Pharmaceuticals Shares Resume Trading; Currently At $0.92/Share,2019-06-14 10:31:00-04:00,AMPE,positive
73029.0,Ampio Pharmaceuticals Shares Halted At $1.05; After Opening Shares Traded In Range Of $1.05-$1.30/Share,2019-06-14 10:26:00-04:00,AMPE,positive
73030.0,Ampio Pharmaceuticals Resume Trade At $1.07 Shares Then Halted For A Second Time,2019-06-14 10:19:00-04:00,AMPE,positive
73031.0,"Ampio Pharmaceuticals Halted On Circuit Breaker; Shares Halted At $0.92, Up 46.03% In The Session",2019-06-14 10:15:00-04:00,AMPE,positive
73032.0,Ampio Pharmaceuticals shares are trading higher after the company announced FDA approval of its special protocol assessment.,2019-06-14 10:09:00-04:00,AMPE,positive
73033.0,Ampio Pharma Announces FDA Approval of the Company's Special Protocol Assessment,2019-06-14 07:31:00-04:00,AMPE,positive
73034.0,"Ampio Pharma Offers Corporate, Clinical, Regulatory Updates",2019-05-22 08:31:00-04:00,AMPE,neutral
73035.0,"Ampio Pharmaceuticals, Inc. Option Alert: Jan, 2021 $1 Calls at the Ask: 800 @ $0.3 vs 1169 OI; Ref=$0.5001",2019-05-21 09:31:00-04:00,AMPE,positive
73036.0,Ampio Pharmaceuticals shares are trading lower after the company announced the FDA recommended that the company not start their confirmatory trial without obtaining FDA concurrence on the trial design.,2019-04-29 08:34:00-04:00,AMPE,positive
73037.0,Ampio Pharma Receives Notice from the FDA to Not Start its Confirmatory Trial Without Obtaining FDA Concurrence on Trial Design,2019-04-29 08:02:00-04:00,AMPE,neutral
73038.0,"Ampio Pharmaceuticals May Offer, Sell Shares Of Common Stock From Time To Time Up To $24.65M Through Canaccord, Acting As Sales Agent",2019-04-15 06:12:00-04:00,AMPE,positive
73039.0,"The Daily Biotech Pulse: FDA Nod For Novartis, Jazz Positive Late-Stage Data For Sleep Disorder Drug, Genfit IPO",2019-03-27 07:52:00-04:00,AMPE,positive
73040.0,Ampio Pharmaceuticals Announces Resubmission of Special Protocol Assessment with FDA for a Confirmatory Phase III Clinical Trial of Ampion for Treatment of Patients Afflicted with Osteoarthritis of the Knee,2019-03-27 04:04:00-04:00,AMPE,positive
73041.0,Ampio Pharma Reports FDA Provided Guidance Co. 'should complete an additional trial of Kellgren Lawrence Grade 4 osteoarthritis of the knee patients with concurrent controls that would be carried out under a Special Protocol Assessment',2019-03-06 08:33:00-05:00,AMPE,positive
73042.0,Ampio Receives Initial Response From FDA Regarding Co.'s Proposed Trial,2019-02-06 08:36:00-05:00,AMPE,neutral
73043.0,"Ampio Pharmaceuticals shares are trading down 23% premarket after the Co announced that the FDA will require a new clinical trial of Ampion, the Co's lead drug for the treatment of severe osteoarthritis of the knee, to support its marketing application.",2018-12-13 07:58:00-05:00,AMPE,positive
73044.0,"Ampio Says FDA's Office of Tissue and Advanced Therapies Met With Co. About Ampion, Provide Guidance Co. Should Complete Added Trial Of KL4 Osteoarthritis Patients",2018-12-13 06:08:00-05:00,AMPE,positive
73045.0,Ampio Pharma Announces the FDA's Office of Tissue and Advanced Therapies Will Provide Guidance by Mid-December if Ampio's Trial Portion of Ampion BLA is Complete Or Will Require an Additional Trial,2018-11-26 08:34:00-05:00,AMPE,positive
73046.0,88 Biggest Movers From Yesterday,2018-11-08 04:54:00-05:00,AMPE,neutral
73047.0,70 Stocks Moving In Wednesday's Mid-Day Session,2018-11-07 12:52:00-05:00,AMPE,neutral
73048.0,Ampio Earlier Announced FDA Has Accepted A Type C Meeting Proposal From Co. And Scheduled Meeting Before End Of November,2018-11-07 10:13:00-05:00,AMPE,positive
73049.0,Ampio Pharmaceuticals shares are trading higher after the FDA accepted a meeting proposal to resolve a dispute regarding the acceptability of a trial for one of two pivotal trials required to file a biologics license application.,2018-11-07 09:25:00-05:00,AMPE,positive
73050.0,'The $GALT stock promoters (many of the same involved with the $AMPE pump and dump) have been salivating in anticipation of these meaningless single-arm combo data. Day traders enjoy!' -Tweet From STAT News' Adam Feuerstein,2018-09-20 08:11:00-04:00,AMPE,negative
73051.0,Ampio Pharmaceuticals' Chief Scientific Officer David Var-Or Retiring Effective September 30th,2018-09-04 17:20:00-04:00,AMPE,positive
73052.0,"Stocks Which Set New 52-Week Low Yesterday, August 9th",2018-08-10 10:05:00-04:00,AMPE,negative
73053.0,77 Biggest Movers From Yesterday,2018-08-10 04:01:00-04:00,AMPE,neutral
73054.0,Mid-Afternoon Market Update: Yelp Jumps Following Strong Q2 Earnings; e.l.f. Beauty Shares Slide,2018-08-09 14:31:00-04:00,AMPE,positive
73055.0,68 Stocks Moving In Thursday's Mid-Day Session,2018-08-09 12:41:00-04:00,AMPE,neutral
73056.0,Mid-Day Market Update: iPass Drops After Q2 Results; Belmond Shares Surge,2018-08-09 12:00:00-04:00,AMPE,positive
73057.0,Ampio Pharmaceuticals shares are trading 38% lower to $0.38 after the company announced public offering of 20M shares at $0.40/share.,2018-08-09 11:11:00-04:00,AMPE,positive
73058.0,Mid-Morning Market Update: Markets Edge Higher; Viacom Profit Beats Views,2018-08-09 10:07:00-04:00,AMPE,positive
73059.0,Ampio Pharma Prices 20M Share Common Stock Offering At $0.40/Share,2018-08-09 08:40:00-04:00,AMPE,positive
73060.0,"The Daily Biotech Pulse: Ampio Slides On Offering, Sangamo's Positive Trial Results, Insys Earnings",2018-08-09 08:39:00-04:00,AMPE,positive
73061.0,40 Stocks Moving In Thursday's Pre-Market Session,2018-08-09 08:09:00-04:00,AMPE,neutral
73062.0,85 Biggest Movers From Yesterday,2018-08-09 05:15:00-04:00,AMPE,neutral
73063.0,"Ampio Pharma Announces Common Stock Offering, No Size Disclosed",2018-08-08 17:56:00-04:00,AMPE,negative
73064.0,Mid-Afternoon Market Update: Crude Oil Down 3.5%; Endo International Shares Surge After Strong Q2 Results,2018-08-08 14:32:00-04:00,AMPE,positive
73065.0,68 Stocks Moving In Wednesday's Mid-Day Session,2018-08-08 12:30:00-04:00,AMPE,neutral
73066.0,Mid-Day Market Update: 3D Systems Climbs On Earnings Beat; Core Molding Technologies Shares Drop,2018-08-08 12:07:00-04:00,AMPE,neutral
73067.0,Mid-Morning Market Update: Markets Edge Lower; CVS Health Profit Tops Expectations,2018-08-08 10:22:00-04:00,AMPE,positive
73068.0,Ampio Pharma shares down 61% after the FDA said the company's trial for AP-0003-C was not adequate. The FDA is recommending Ampio performs a randomized trial,2018-08-07 18:11:00-04:00,AMPE,positive
73069.0,Ampio Pharmaceuticals 8-K Indicates FDA Said In Response Letter That It Does Not Consider AP-0003-C Trial To Be Adequate And Well-Controlled Clinical Trial And Recommended Co. Performs Randomized Trial With Concurrent Trial; Shares Down 54.7% After Hours,2018-08-07 17:43:00-04:00,AMPE,positive
73070.0,36 Stocks Moving In Tuesday's Pre-Market Session,2018-08-07 08:04:00-04:00,AMPE,neutral
73071.0,52 Biggest Movers From Yesterday,2018-08-07 05:19:00-04:00,AMPE,neutral
73072.0,66 Biggest Movers From Friday,2018-08-06 05:36:00-04:00,AMPE,neutral
73073.0,"'Someone is paying for a new $AMPE stock promotion campaign on Twitter, Seeking Alpha, message boards and web sites like below:'-STAT's Adam Feuerstein Tweets",2018-07-27 12:17:00-04:00,AMPE,positive
73074.0,36 Stocks Moving In Friday's Pre-Market Session,2018-07-27 08:08:00-04:00,AMPE,neutral
73075.0,38 Biggest Movers From Yesterday,2018-07-24 04:06:00-04:00,AMPE,neutral
73076.0,34 Stocks Moving In Monday's Mid-Day Session,2018-07-23 12:42:00-04:00,AMPE,neutral
73077.0,41 Biggest Movers From Friday,2018-07-23 04:04:00-04:00,AMPE,neutral
73078.0,Ampio Pharmaceuticals Shares Up 15.7% For Session Despite No Company-Specific News Or Fundamental Catalyst To Justify Price Action; Watch For Technical Indicators And Price Action,2018-06-22 14:35:00-04:00,AMPE,positive
73079.0,Ampio Announces 2 Peer-Reviewed Articles ON Clinical Application Of Ampion,2018-06-05 08:32:00-04:00,AMPE,neutral
73080.0,42 Biggest Movers From Yesterday,2018-05-30 05:30:00-04:00,AMPE,neutral
73081.0,37 Stocks Moving In Tuesday's Mid-Day Session,2018-05-29 12:44:00-04:00,AMPE,neutral
73082.0,Ampio  Awarded U.S. Patent For Treatment Of Joint Conditions That Provides Method Protection Until 2035 For Multiple Injections Of Ampion,2018-05-29 08:31:00-04:00,AMPE,positive
73083.0,UPDATE: Ampio Says Is Actively Pursuing Endeavors To Strengthen Its Balance Sheet,2018-05-14 08:43:00-04:00,AMPE,positive
73084.0,"UPDATE: Ampio Says Co. Has Hired Added Internal Staff Dedicated Solely To Supporting Efforts Of BLA Consultant, Parexel In Preparation For Chemistry, Manufacturing, Controls Filing",2018-05-14 08:42:00-04:00,AMPE,positive
73085.0,UPDATE: Ampio Says FDA Discussions Ongoing Related To Development Process Prior To Filing Of BLA,2018-05-14 08:42:00-04:00,AMPE,neutral
73086.0,"UPDATE: Ampio Pharma Reports Received Total Of $3.1M From Investor Warrants, Stock Options Being Exercised In Q1",2018-05-14 08:41:00-04:00,AMPE,neutral
73087.0,Ampio Provides Company Update,2018-05-14 08:31:00-04:00,AMPE,neutral
73088.0,36 Biggest Movers From Yesterday,2018-05-01 05:02:00-04:00,AMPE,neutral
73089.0,Ampio Pharma Says Received Notification Letter From NYSE Confirming Co. Now In Full Compliance With Listing Requirements,2018-04-12 17:41:00-04:00,AMPE,neutral
73090.0,Ampio Pharma Says Has Begun Prelim. Discussions With FDA On Details OF BLA Submission Process For Ampion,2018-04-12 17:40:00-04:00,AMPE,neutral
73091.0,"'Ampio Pharmaceuticals: Cash Critically Low, Pattern Of Exaggerated Claims Continues'",2018-04-12 10:10:00-04:00,AMPE,negative
73092.0,36 Biggest Movers From Yesterday,2018-04-11 05:17:00-04:00,AMPE,neutral
73093.0,25 Stocks Moving In Tuesday's Mid-Day Session,2018-04-10 12:40:00-04:00,AMPE,neutral
73094.0,41 Biggest Movers From Yesterday,2018-03-23 04:52:00-04:00,AMPE,neutral
73095.0,"Ampio Pharma Says AP-003-C Showed Primary Endpoint Achieved Statistical Significance , Ampion Was Statistically Superior",2018-03-15 17:05:00-04:00,AMPE,positive
73096.0,40 Biggest Movers From Yesterday,2018-02-21 05:38:00-05:00,AMPE,neutral
73097.0,"Ampio Pharma Shares Down 10.5% Tues., Continuing 14% Decline From Fri.; Not Seeing News To Justify Price Action; Earlier Saw Several Bearish Option Alerts: Mar. $2, $4 Puts Saw Notable Activity",2018-02-20 15:01:00-05:00,AMPE,positive
73098.0,Ampio Pharma Option Alert: Mar 16 $4 Puts Sweep (26) at the Ask: 500 @ $1.4 vs 11 OI; Ref=$2.7501,2018-02-20 09:48:00-05:00,AMPE,positive
73099.0,45 Biggest Movers From Friday,2018-02-20 04:50:00-05:00,AMPE,neutral
73100.0,36 Stocks Moving In Friday's Mid-Day Session,2018-02-16 12:25:00-05:00,AMPE,neutral
73101.0,36 Biggest Movers From Yesterday,2018-01-05 05:48:00-05:00,AMPE,neutral
73102.0,33 Stocks Moving In Thursday's Mid-Day Session,2018-01-04 12:25:00-05:00,AMPE,neutral
73103.0,"Adam Feuerstein Tweets (2/2): They're the black hole of credibility. But hey, other than that, it's great!",2018-01-04 10:53:00-05:00,AMPE,positive
73104.0,"Adam Feuerstein Tweets (1/2): Yet, $AMPE data collected to date demonstrates Ampion does not help people bc it lacks potency. And management carries significant credibility deficit.",2018-01-04 10:52:00-05:00,AMPE,negative
73105.0,40 Biggest Movers From Yesterday,2018-01-04 05:30:00-05:00,AMPE,neutral
73106.0,35 Biggest Movers From Yesterday,2018-01-03 05:03:00-05:00,AMPE,neutral
73107.0,"Ampio Pharma Shares Resume Trade, Continue Lower, Now Down 28.2% For Session",2018-01-02 13:44:00-05:00,AMPE,neutral
73108.0,"Ampio Pharma Shares Halted On Circuit Breaker, Down 24.7% For Session; Downside Intensified As $3.50 Support Level Was Broken",2018-01-02 13:33:00-05:00,AMPE,negative
73109.0,28 Stocks Moving In Tuesday's Mid-Day Session,2018-01-02 13:09:00-05:00,AMPE,neutral
73110.0,"STAT News' Adam Feuerstein Tweets: With an arthritis drug no better than common saline, $AMPE shot at FDA approval is dim statnews.com/2018/01/02/art… The bear thesis, explained.",2018-01-02 13:09:00-05:00,AMPE,positive
73111.0,22 Stocks Moving In Tuesday's Pre-Market Session,2018-01-02 08:11:00-05:00,AMPE,neutral
73112.0,32 Biggest Movers From Yesterday,2017-12-29 05:15:00-05:00,AMPE,neutral
73113.0,31 Stocks Moving In Thursday's Mid-Day Session,2017-12-28 12:56:00-05:00,AMPE,neutral
73114.0,32 Biggest Movers From Yesterday,2017-12-27 04:59:00-05:00,AMPE,neutral
73115.0,30 Stocks Moving In Tuesday's Mid-Day Session,2017-12-26 14:20:00-05:00,AMPE,neutral
73116.0,36 Stocks Moving In Tuesday's Mid-Day Session,2017-12-19 12:25:00-05:00,AMPE,neutral
73117.0,30 Stocks Moving In Tuesday's Pre-Market Session,2017-12-19 08:08:00-05:00,AMPE,neutral
73118.0,40 Biggest Movers From Yesterday,2017-12-19 05:15:00-05:00,AMPE,neutral
73119.0,"Ampio Pharma Reports Results For Primary, Secondary Endpoints Of Phase 3 Trial Of Ampion In Severe OAK",2017-12-14 07:17:00-05:00,AMPE,negative
73120.0,40 Biggest Movers From Wednesday,2017-11-24 05:50:00-05:00,AMPE,neutral
73121.0,35 Stocks Moving In Wednesday's Mid-Day Session,2017-11-22 12:25:00-05:00,AMPE,neutral
73122.0,Ampio Pharma Shares Indicated Higher Following Release Highlighting Publication Of Co.'s Treatment For Sever Osteoarthritis Of The Knee,2017-11-22 08:36:00-05:00,AMPE,positive
73123.0,Ampio Pharma Reports Commencement Of Open Label Extension Study For Support Of Commercial Label Of Repeat Administration Of Ampion,2017-11-15 08:41:00-05:00,AMPE,positive
73124.0,35 Biggest Movers From Yesterday,2017-10-17 04:52:00-04:00,AMPE,neutral
73125.0,30 Stocks Moving In Monday's Mid-Day Session,2017-10-16 12:32:00-04:00,AMPE,neutral
73126.0,Asterias Biotherapeutics Prices Registered Direct Offering at $2.60/Share,2017-10-16 08:33:00-04:00,AMPE,neutral
73127.0,Amio Pharma Prices $6.75M Registered Direct Offering at $0.875/Share,2017-10-16 08:32:00-04:00,AMPE,neutral
73128.0,Ampio Pharma Reports Acceptance Of Pooled Ampion Trial Results In Patients With Severe Osteoarthritis Of The Knee,2017-10-12 08:35:00-04:00,AMPE,positive
73129.0,"Ampio Recieves Non-compliance Listing Notice From NYSE, Has Until 3/1/19 To Regain Compliance",2017-09-07 16:12:00-04:00,AMPE,neutral
73130.0,"Ampio Pharma Reports Allowance Of Important Composition, Methods Patent In USA Complimenting Series Of Patents On Ampion (127 Issued, 80 Pending)",2017-08-08 08:40:00-04:00,AMPE,positive
73131.0,Ampio Injects Initial Patient in Final Pivotal Clinical Trial for Ampion BLA,2017-06-22 08:31:00-04:00,AMPE,neutral
73132.0,Ampio Pharma Announces Will Not Renew Contract Of Gregory Gould; Tom Chilcott Named As Interim CFO,2017-06-12 08:31:00-04:00,AMPE,neutral
73133.0,"Ampio Pharma Reports Pricing of $6.3M Common Stock, Warrants Offering at Combined Price of $0.60/Share",2017-06-02 12:20:00-04:00,AMPE,neutral
73134.0,Ampio Starts Pivotal Trial of Ampion,2017-05-01 08:09:00-04:00,AMPE,neutral
73135.0,"Ampio Pharma Reports Waiver, Consent Letter Deal with CVI Investments",2017-03-28 08:02:00-04:00,AMPE,positive
73136.0,Ampio Announces Locust Walk Will Serve as Strategic Advisor to Co.,2017-03-20 08:34:00-04:00,AMPE,neutral
73137.0,UPDATE: Ampio Says Plans to Advance All Necessary BLA Activities in Parallel to Expedite Path to Potential FDA Approval,2017-03-20 08:33:00-04:00,AMPE,positive
73138.0,Ampio Pharma Says FDA's Responder Rate Definition Would Have All Previous Ampion Single Injections Trials Successfully Meeting Trial Endpoint,2017-03-20 08:33:00-04:00,AMPE,positive
73139.0,"Ampio Receives Guidance from the FDA and Proposes a Path for Approval for Single-Injection Ampion, Proposed Pre-Approval Study",2017-02-27 08:35:00-05:00,AMPE,positive
73140.0,Ampio Pharma Reports Publication of Manuscript Covering 'Low Dose Danazol in Combination With Renin Angiotensin Inhibitors' Accepted for Acta Ophthalmologica,2016-10-04 08:36:00-04:00,AMPE,negative
73142.0,Ampio Pharma Reports Completion Of Enrollment For AP-011 Study,2016-09-29 14:53:00-04:00,AMPE,neutral
73143.0,Ampio Reports Peer-Reviewed Publication on the Potential use of Ampion in New Clinical Indications,2016-09-08 12:11:00-04:00,AMPE,neutral
73144.0,CVI Investments Reports 8.8% Passive Stake in Ampio Pharmaceuticals in 13G,2016-09-07 16:35:00-04:00,AMPE,positive
73145.0,Ampio Reports Pricing Of 5M Registered Shares In Direct Offering,2016-08-29 11:11:00-04:00,AMPE,positive
73146.0,Ampio Pharmaceuticals Files Meeting Request And Briefing Document With FDA To Seek Guidance On BLA For Ampion,2016-08-03 08:05:00-04:00,AMPE,neutral
73147.0,Mid-Afternoon Market Update: Dow Rises More Than 200 Points; Care.com Shares Gain Following Alphabet Investment,2016-06-30 14:39:00-04:00,AMPE,positive
73148.0,10 Biggest Mid-Day Losers For Thursday,2016-06-30 13:10:00-04:00,AMPE,negative
73149.0,Ampio Pharma Reports Will Request FDA Approval for Treatment of Pain Due to Severe Osteoarthritis of the Knee,2016-06-30 08:03:00-04:00,AMPE,negative
73150.0,Ampio Reports Additional Peer-Reviewed Publications on Ampion,2016-05-03 08:35:00-04:00,AMPE,neutral
73151.0,Knoll Capital Management Reports  6.5% Stake in Ampio Pharmaceuticals in 13G,2016-03-01 12:20:00-05:00,AMPE,neutral
73152.0,Ampio Intends to Distribute Aytu BioScience Stock to Ampio Shareholders,2015-11-02 08:32:00-05:00,AMPE,neutral
73153.0,"Ampio Pharmaceuticals, Inc. Announces Updates On the Regulatory Path for FDA Approval of Optina™, an Oral Treatment for Diabetic Macular Edema (DME)",2015-10-14 09:02:00-04:00,AMPE,positive
73154.0,8-K from Ampio Pharma Shows nit Aytu Bioscience Entered MSA with Biovest Int'l for Providing of Manufacturing Services to Aytu,2015-10-13 16:37:00-04:00,AMPE,neutral
73155.0,Morning Market Gainers,2015-09-22 09:57:00-04:00,AMPE,neutral
73156.0,AMPIO Receives Special Protocol Assessment from FDA; Commences Second Phase III pivotal trial of Ampion,2015-09-22 08:04:00-04:00,AMPE,positive
73157.0,"Adam Feuerstein ‏@adamfeuerstein  Given the $FLXN blow up, $AMPE should trade at zero. Literally, zero.",2015-09-08 16:54:00-04:00,AMPE,neutral
73158.0,Costa: 7 Stocks Market Technicians Should Keep An Eye On,2015-08-22 17:20:00-04:00,AMPE,neutral
73159.0,Ampio Pharmaceuticals Reports Additional Statistically Significant Study Results for Optina in the Treatment of Diabetic Macular Edema,2015-06-22 08:31:00-04:00,AMPE,positive
73160.0,AMpio Pharmaceuticals Announces Synergistic Effects Of Ampion,2015-06-09 08:39:00-04:00,AMPE,neutral
73161.0,8-K from Ampio Pharma Shows Co. Has Purchased Jazz Pharma's ProstaScint for $1M at Closing Plus Added $500K Payable Within Five Days After Transfer,2015-05-27 16:16:00-04:00,AMPE,neutral
73162.0,Ampio CMO Says Optina Results Not Significant,2015-05-21 15:53:00-04:00,AMPE,negative
73163.0,Morning Market Gainers,2015-05-21 09:49:00-04:00,AMPE,neutral
73164.0,Ampio Pharmaceuticals Reports Positive Study Results on Optina For Treatment of Diabetic Macular Edema,2015-05-21 08:01:00-04:00,AMPE,positive
73165.0,Morning Market Losers,2015-04-20 09:51:00-04:00,AMPE,negative
73166.0,Ampio Pharmaceuticals Shares Fall 46% Premarket Following Announcement of Failure of STRIDE Study AP008 to Reach Primary Endpoint,2015-04-20 08:57:00-04:00,AMPE,negative
73167.0,UPDATE: Ampio Pharmaceuticals Multiple-Injection STRIDE Study AP008 Did Not Reach Primary Endpoint Against Saline Control,2015-04-20 08:48:00-04:00,AMPE,neutral
73168.0,AMPIO Announces Ampion STRIDE Study Results,2015-04-20 08:45:00-04:00,AMPE,neutral
73169.0,Ampio Pharmaceuticals Shares Move Lower; May be Attributed to Seeking Alpha Post,2015-01-27 13:55:00-05:00,AMPE,neutral
73170.0,Ampio Announces Results Of The Open Label Portion Of The Multiple Intra-articular Injections Study Of Ampion In Patients With Osteoarthritis Of The Knee At Week Twenty Of The Trial,2014-12-01 08:03:00-05:00,AMPE,neutral
73171.0,Ampio Announces Results of the Open Label Portion of the Multiple Intra-articular Injections Study of Ampion ,2014-10-16 16:04:00-04:00,AMPE,neutral
73172.0,Ampio Shares Move Lower; May be Attributed to Negative Adam F/Street.com Article ,2014-09-03 12:10:00-04:00,AMPE,negative
73173.0,"Ampio Offers Update on Phase III Multicenter, Double-Blind STEP Study of Ampion",2014-09-02 07:57:00-04:00,AMPE,neutral
73174.0,Ampio Pharma Announces Responses to Questions Related to STEP Study,2014-08-25 08:03:00-04:00,AMPE,neutral
73175.0,Morning Market Losers ,2014-08-22 09:58:00-04:00,AMPE,negative
73176.0,Benzinga's Top Downgrades,2014-08-22 09:44:00-04:00,AMPE,positive
73177.0,Jefferies Downgrades Ampio Pharmaceuticals To Hold,2014-08-22 08:33:00-04:00,AMPE,neutral
73178.0,"Jefferies Downgrades Ampio Pharmaceuticals, Inc. to Hold, Lowers PT to $5.00",2014-08-22 06:29:00-04:00,AMPE,negative
73179.0,Morning Market Losers ,2014-08-21 10:02:00-04:00,AMPE,negative
73180.0,"Ampio Says Release of Data Will Be Delayed, FDA Agreed to Analyze Step Trial As Supportive Data for BLA",2014-08-21 08:02:00-04:00,AMPE,positive
73181.0,Ampio Announces Positive Results From Multiple Injection Study,2014-08-05 08:01:00-04:00,AMPE,positive
73182.0,Ampio Pharma Says FDA Gave Positive Response Regarding Starting Production of Ampion in New Facility,2014-07-30 08:06:00-04:00,AMPE,positive
73183.0,"Jefferies Initiates Coverage on Ampio Pharmaceuticals, Inc. at Buy, Announces $14.00 PT",2014-06-27 06:36:00-04:00,AMPE,neutral
73184.0,Adam Feuerstein Tweet: $AMPE Expects Investors to Wear Beer Goggles Before Reading Eye-Drug Press Release —> thestreet.com/story/12756754,2014-06-25 13:08:00-04:00,AMPE,neutral
73185.0,"Ampio Pharma Announces Closing of Enrollment in OptimEyes Study, Cites Positive Feedback",2014-06-25 08:10:00-04:00,AMPE,positive
73186.0,Ampio Announces Gregory Gould CFO,2014-06-05 08:02:00-04:00,AMPE,neutral
73187.0,Ampio Pharmaceuticals' Vyrix Enters into an Agreement with Paladin Labs for Exclusive Rights to Zertane in Canada,2014-04-10 08:05:00-04:00,AMPE,positive
73188.0,Ampio Pharma to Present Results of 20 Weeks Extension of Ampion SPRING Study at Western Orthopedic Association,2014-04-09 08:11:00-04:00,AMPE,neutral
73189.0,"Ampio Pharma Closes Sale of 9.775M Shares of Stock, Sees Net Proceeds ~$63.3M",2014-03-05 10:55:00-05:00,AMPE,positive
73190.0,UPDATE: Ampio Pharmaceuticals Shares Fall 7% Premarket on Pricing of 8M Share Offering at $7.00,2014-02-28 08:23:00-05:00,AMPE,positive
73191.0,Ampio Pharmaceuticals Prices 8.5M Share Offering at $7.00/Share,2014-02-27 21:07:00-05:00,AMPE,positive
73192.0,Ampio Pharma Files $100M Mixed Securities Shelf,2013-12-26 17:03:00-05:00,AMPE,positive
73193.0,Ampio Pharmaceuticals Spins-Off Sexual Dysfunction Business ,2013-12-13 13:01:00-05:00,AMPE,negative
73194.0,"Ampio Pharma Receives FDA Confirmation Spring Study is Pivotal, Will Begin the Final Pivotal Trial for Ampion BLA",2013-12-02 08:00:00-05:00,AMPE,neutral
73195.0,Ampio Hides Need For New Eye Drug Study in SEC Filing -Adam F/The Street,2013-11-25 08:23:00-05:00,AMPE,negative
73196.0,"Ampio Pharma Announces Results from Panel Review of the Interim Analysis of the Optina(TM) Trial, FDA Agrees to 505(B) 2 Pathway",2013-10-07 08:06:00-04:00,AMPE,positive
73197.0,"Ampio Pharmaceuticals, Inc. Announces Additional Positive Results for Ampion(TM) in Osteoarthritis of the Knee Clinical Trial",2013-09-30 08:08:00-04:00,AMPE,positive
73198.0,"Top Double Digit Winners and Losers From Wednesday, August 14, 2013",2013-08-15 13:38:00-04:00,AMPE,positive
73199.0,Morning Market Movers ,2013-08-14 10:01:00-04:00,AMPE,neutral
73200.0,Ampio Pharmaceuticals Announces Ampion Study Meets Primary Endpoint with High Statistical Significance; All Primary Study Objectives were Achieved,2013-08-14 08:05:00-04:00,AMPE,positive
73201.0,Ampio Responds to Street.com Article,2013-08-07 12:57:00-04:00,AMPE,neutral
73202.0,Ampio Pharmaceuticals Spikes Lower; May be Attributed to Adam F/Street.com Article,2013-08-06 10:52:00-04:00,AMPE,negative
73203.0,Ampio Pharma's Luoxis Diagnostics Reports Positive Results from First Study of Proprietary Diagnostic Platform,2013-06-20 08:05:00-04:00,AMPE,positive
73204.0,Afternoon Market Losers,2013-06-05 15:40:00-04:00,AMPE,negative
73205.0,Ampio Pharmaceuticals Completes Enrollment in Run-In SPRING study of Ampion in Osteoarthritis of the Knee,2013-04-25 08:02:00-04:00,AMPE,neutral
73206.0,A Peek Into The Market Before The Trading Starts,2013-04-02 07:09:00-04:00,AMPE,neutral
73207.0,Ampio Receives FDA Acceptance for Clinical Trial of Ampion for Treatment of Osteoarthritis of the Knee,2013-04-02 06:05:00-04:00,AMPE,positive
73208.0,"Benzinga's Small Cap Movers for Monday March 11, 2013",2013-03-11 18:33:00-04:00,AMPE,neutral
73209.0,"UPDATE: Aegis Capital Reiterates Buy Rating, Raises PT on Ampio Pharmaceuticals on Clinical Milestones",2013-03-04 08:09:00-05:00,AMPE,neutral
73210.0,"Aegis Capital Maintains Buy on Ampio Pharmaceuticals, Inc., Raises PT to $12.00",2013-03-01 16:40:00-05:00,AMPE,neutral
73211.0,Ampio Pharmaceuticals Begins Clinical Trial of Optina for Diabetic Macular Edema,2013-02-27 05:54:00-05:00,AMPE,neutral
73212.0,A Peek Into The Market Before The Trading Starts,2013-02-25 07:13:00-05:00,AMPE,neutral
73213.0,Ampio Pharmaceuticals Announces Phase 3 Ampion Study for Osteoarthritis of the Knee to Include a Dose-Escalation Run-in Study,2013-02-25 05:56:00-05:00,AMPE,neutral
73214.0,A Peek Into The Market Before The Trading Starts,2013-01-22 07:15:00-05:00,AMPE,neutral
73215.0,FDA Accepts Ampio Pharmaceuticals IND for Optina for Treatment of Diabetic Macular Edema,2013-01-22 05:50:00-05:00,AMPE,positive
73216.0,Negative Seeking Alpha Article on Ampio Pharmaceuticals,2012-08-28 13:49:00-04:00,AMPE,negative
73217.0,Ampio Pharmaceuticals Rises 18% on Positive Motley Fool Report on Thursday,2012-08-24 11:13:00-04:00,AMPE,positive
73218.0,"Ampio Advances NCE001 Cancer Drug into Preclinical Development Following Successful Recent Financing and the Granting of Patents in USA, Canada, Europe and China  ",2012-07-16 07:29:00-04:00,AMPE,positive
73219.0,"From Earlier: Ampio Pharmaceuticals Announces Pricing of Public Offering of 4,6M Shares at $3.25",2012-07-13 07:43:00-04:00,AMPE,positive
73220.0,Ampio's CEO and CSO Send Message to Shareholders ,2012-07-03 06:31:00-04:00,AMPE,neutral
73221.0,Ampio Pharmaceuticals Spokesperson Confirms Seeking Alpha's Richard Cavalli Was Flown Out to Company Headquarters,2012-07-02 14:19:00-04:00,AMPE,neutral
73222.0,Morning Market Movers,2012-07-02 09:46:00-04:00,AMPE,neutral
73223.0,"Ampio Contracts with Syngene to Manufacture Zertane-ED, its Recently Patented Combination Drug",2012-07-02 06:45:00-04:00,AMPE,neutral
73224.0,From Earlier: Ampio Reports Successful Type B Pre-IND Meeting with the FDA for its Drug Zertane™ to treat Premature Ejaculation (PE)  ,2012-06-21 07:50:00-04:00,AMPE,positive
73225.0,These 5 Small Cap Stocks Are Up Better Than 10% Today,2012-06-11 13:44:00-04:00,AMPE,positive
73226.0,Ampio Pharmaceuticals Rises 23% on Positive Clinical Trial Results for Optina,2012-06-11 09:47:00-04:00,AMPE,positive
73227.0,Benzinga's Top Pre-Market Gainers ,2012-06-11 08:28:00-04:00,AMPE,positive
73228.0,From Earlier: Ampio Announces Positive Clinical Trial Results for the Treatment of Diabetic Macular Edema with Orally Administered Optina™  ,2012-06-11 08:12:00-04:00,AMPE,positive
73229.0,Ampio Pharmaceuticals Reports Pre-IND Meeting With the FDA to Obtain Clinical Path Guidance for Ampion,2012-05-11 11:29:00-04:00,AMPE,neutral
73230.0,A Peek Into The Market Before The Trading Starts,2012-05-11 07:29:00-04:00,AMPE,neutral
73231.0,Ampio Pharmaceuticals Reports Pre-IND Meeting With the FDA to Obtain Clinical Path Guidance for Ampion,2012-05-11 07:01:00-04:00,AMPE,neutral
73232.0,Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina for the treatment of Diabetic Macular Edema ,2012-04-27 07:08:00-04:00,AMPE,positive
73233.0,A Peek Into The Market Before The Trading Starts,2012-04-09 07:20:00-04:00,AMPE,neutral
73234.0,Ampio Submits Type B Pre IND Meeting Request to the FDA for Zertane™ ,2012-04-09 07:01:00-04:00,AMPE,neutral
73235.0,Ampio Reaches Agreement with the TGA for the Submission Plan for Zertane in Australia ,2012-04-02 07:01:00-04:00,AMPE,positive
73236.0,Ampio Pharmaceuticals Announces the Licensing of Zertane to FBM Industria Farmaceutica Ltda to Commercialize in Brazil ,2012-03-22 07:01:00-04:00,AMPE,neutral
73237.0,"Monday's NASDAQ Winners: RCON, AMPE, SAPX, AGEN",2012-03-20 12:24:00-04:00,AMPE,positive
73238.0,Ampio Strengthens Patent Protection for Lead Drug Ampion,2012-03-20 07:01:00-04:00,AMPE,positive
73239.0,Why Ampio's Rebound Run May Not Be Done,2012-03-19 16:48:00-04:00,AMPE,neutral
73240.0,Ampio Pharma Soars 45% on Positive Clinical Trial ,2012-03-19 10:07:00-04:00,AMPE,positive
73241.0,Morning Market Movers,2012-03-19 09:47:00-04:00,AMPE,neutral
73243.0,"Hedge Fund Shkreli: Ampio Pharmaceuticals PR this Morning is  ""Laughable""",2012-01-31 09:01:00-05:00,AMPE,neutral
73244.0,"Ampio Pharmaceuticals Announces Statistically Significant Improvement in Pain Relief for its Lead Product, Ampion in the Osteoarthritis of the Knee Trial. ",2012-01-31 07:01:00-05:00,AMPE,positive
73245.0,Scorecard and New Picks: Technical Value Fishing Under $5,2012-01-26 07:18:00-05:00,AMPE,positive
73246.0,Ampio CEO Taking Compassionate Leave,2012-01-09 07:01:00-05:00,AMPE,positive
73247.0,Ampio Pharmaceuticals Completes Expanded Patient Enrollment for Ampion In Osteoarthritis of the Knee Clinical Trial in Australia  ,2012-01-03 07:01:00-05:00,AMPE,neutral
73248.0,Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion,2011-12-22 11:50:00-05:00,AMPE,positive
73249.0,Ampio Pharmaceuticals Announces Registered Direct Common Stock Offering of Approximately $9.436M ,2011-12-21 10:35:00-05:00,AMPE,neutral
73250.0,Ampio Says Factually Inaccurate and Purposely Misleading Information Panicked Market,2011-12-16 09:20:00-05:00,AMPE,negative
73251.0,Ampio Responds to What May Be a Coordinated Short Selling Attack Against the Firm's Stock  ,2011-12-16 08:37:00-05:00,AMPE,negative
73252.0,Ampio Responds to Recent Publications by Anonymous Short Sellers ,2011-12-16 07:31:00-05:00,AMPE,neutral
73254.0,Ampio Pharmaceuticals Announces Agreement to Acquire Key Drug Delivery Technology ,2011-12-05 08:01:00-05:00,AMPE,positive
73255.0,"Financial Breakfast: Morning News Summary for November 10, 2011",2011-11-10 07:40:00-05:00,AMPE,neutral
73256.0,Ampio Pharmaceuticals Announces Positive Results on Ampion Trial for Relief of Nasal Inflammation ,2011-11-10 07:06:00-05:00,AMPE,positive
73257.0,Ampio Pharmaceuticals Announces a Proof of Concept Trial of Danazol in the Treatment of Allergic Rhinitis Supports Mechanism of Action of Optina,2011-10-18 07:26:00-04:00,AMPE,positive
73258.0,Ampio Pharmaceuticals Completes Treatment Phase of the Ampion-in-Knee Clinical Trial for Osteoarthritis  ,2011-10-13 08:04:00-04:00,AMPE,neutral
73259.0,"Ampio Announces the Presentation of a Publication on Ampion, its Drug Candidate to Address Human Inflammation",2011-10-10 08:05:00-04:00,AMPE,neutral
73260.0,Ampio Pharmaceuticals Receives Notice of Allowance of its Two Patent Applications on the Combination of Zertane with Erectile Dysfunction Drugs in Canada  ,2011-09-28 08:03:00-04:00,AMPE,negative
73261.0,Ampio Pharmaceuticals' Executes License and Development Agreement with Daewoong to Commercialize Zertane in South Korea  ,2011-09-08 08:07:00-04:00,AMPE,positive
73262.0,Zertane Clinical Results Published in the Journal European Urology ,2011-08-30 10:37:00-04:00,AMPE,neutral
73263.0,Ampio Pharmaceuticals Announces Hiring of Deborah Knobelman as Chief Business Officer ,2011-08-22 08:03:00-04:00,AMPE,neutral
73264.0,Ampio Pharmaceuticals Announces Treatment of First Patient in Phase 1b Ampion-In -Knee Trial for Osteoarthritis in Australia,2011-07-05 08:05:00-04:00,AMPE,neutral
73265.0,Ampio Pharmaceuticals Releases Results From Phase III Clinical Trial of Zertane for the Treatment of Premature Ejaculation,2011-06-27 08:02:00-04:00,AMPE,neutral
73266.0,Ampio Pharmaceuticals Announces Initiation of Phase 1B Clinical Trial for Its Anti-inflammatory Drug Ampion,2011-05-31 13:00:00-04:00,AMPE,neutral
